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We describe clinical and parasitologic features of in 
vivo and in vitro Plasmodium falciparum resistance to qui-
nine in a nonimmune traveler who returned to France from 
Senegal in 2007 with severe imported malaria. Clinical qui-
nine failure was associated with a 50% inhibitory concentra-
tion of 829 nmol/L. Increased vigilance is required during 
treatment follow-up.
R
esistance of Plasmodium falciparum to antimalarial 
drugs is one the most worrisome problems in tropical 
medicine. Quinine remains the ﬁ  rst-line antimalarial option 
for treatment of patients with complicated malaria in Eu-
rope and Africa. However, emergence of quinine resistance 
has been sparsely documented (1). Maximizing the efﬁ  cacy 
and longevity of quinine as a drug to control malaria will 
critically depend on pursuing intensive research into iden-
tifying in vitro markers and implementing active in vitro 
and in vivo surveillance programs such as those supported 
by the World Antimalarial Resistance Network. Such mo-
lecular markers are needed to monitor temporal trends in 
parasite susceptibility (2). We report quinine-resistant P. 
falciparum malaria in a patient who returned to France 
from Senegal.
The Patient
A 17-year-old white man from France spent ≈2 months 
(April and most of May) in 2007 in Dielmo, Senegal, where 
malaria is highly endemic and shows intense perennial 
transmission (3). He did not use antimalarial prophylaxis 
or protection against mosquitoes. After returning to France, 
he was admitted to the Bordeaux University Hospital Cen-
ter on May 27, 2007 (day 0). The patient had P. falciparum 
parasitemia level of 7% and a 2-day history of fever, my-
algia, vomiting, and rapid deterioration of consciousness 
into an arousable coma. A diagnosis of severe malaria with 
cerebral involvement was conﬁ  rmed.
Intravenous quinine formiate (loading dose 17 mg/
kg) was administered, followed by a maintenance dose 
(8.3 mg/kg 3×/day for 7 days). The patient was afebrile on 
day 3, and his thin and thick blood ﬁ  lms became negative 
for P. falciparum on day 6. He was discharged from the 
hospital on day 7. However, on day 26, he relapsed and 
had fever and vomiting. He was hospitalized again on day 
27 with a core temperature of 40°7C, deterioration of con-
sciousness, and a P. falciparum parasitemia level of 4%. 
He received the same regimen of quinine formiate plus 
intravenous clindamycin (10 mg 3×/day) for 7 days. His 
serum quinine level (free and bound drug assayed by high 
performance liquid chromatography) taken immediately 
before the fourth drug dose was low (7 mg/L). The patient 
was then given quinine (10 mg/kg 3×/day from day 30 
through day 34). Serum quinine levels then increased and 
fever cleared within 72 hours. However, a blood smear 
was positive on day 34.
Because of the treatment failure with quinine and clin-
damycin, the patient was treated with oral co-artemether 
(20 mg artemether and 120 mg lumefantrine, given as 4 
tablets, followed by 4 tablets after 8 hours, and 4 tablets 2×/
day for 2 days; total = 24 tablets). Parasitic clearance was 
observed within 48 hours. Blood smears and results of a 
PCR for P. falciparum were negative from day 36 through 
day 62. No further recrudescence occurred over the next 
12 months.
The isotopic microdrug susceptibility tests used have 
been described (4). The chloroquine-susceptible 3D7 P. 
falciparum clone (Africa) and the chloroquine-resistant 
W2 clone (Indochina), after 2 rounds of sorbitol synchroni-
zation, were used as controls. The 50% inhibitory concen-
tration (IC50) values for 12 antimalarial drugs for the study 
isolate and these 2 controls are shown in the Table. The 
strain isolated on day 27 showed reduced susceptibility to 
quinine (IC50 829 nmol/L, threshold 800 nmol/L) and chlo-
roquine (472 nmol/L, threshold 100 nmol/L). The IC50 for 
clindamycin was 39 μmol/L (the in vitro resistance cutoff 
value was not determined). The isolate was susceptible to 
all other antimalarial drugs tested. Phenotypes and geno-
types were assessed only for parasites obtained on day 27.
We concurrently screened blood samples for resis-
tance-associated point mutations. A sequence contain-
ing the ms4760 microsatellite was ampliﬁ  ed as described 
(5). The observed ms4760–18 proﬁ  le was composed of 2 
DNNND repeats and 2 DDDNHNDNHNN repeats. Geno-
typing of the P. falciparum chloroquine resistance trans-
porter (Pfcrt) gene, which encodes a transport protein 
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involved in chloroquine resistance (K76T), and the dihy-
droopteroate synthase gene, which encodes the sulfadoxine 
target (A437G), identiﬁ  ed the resistant allele in our isolate 
(6). There was no mutation in codon 268, which encodes 
the atovaquone target (4). The isolate had only 1 copy of 
the P. falciparum multidrug resistance (Pfmdr1) gene and a 
mutation in codon 184, which suggested in vitro suscepti-
bility to meﬂ  oquine (7). Ampliﬁ  cation of DNA from para-
sites obtained on day 0 and preserved on ﬁ  xed and stained 
thin blood ﬁ  lms by a modiﬁ  cation of the procedure of Edoh 
et al. (8) was not successful.
Conclusions
Quinine remains a reliable treatment for patients with 
complicated or severe P. falciparum malaria outside south-
ern Asia. Clinical failure with quinine used alone or in 
combination with clindamycin is common in Africa. In our 
case-patient, a correlation between the results of the in vivo 
and in vitro assessments was demonstrated at day 27. Be-
cause of the lack of reliable data on the correlation between 
quinine IC50 and clinical failure, arbitrary IC50 cutoff values 
were chosen for in vitro quinine resistance (300 nmol/L, 
500 nmol/L, or 800 nmol/L) (9).
Quinine resistance appears to share common char-
acteristics with chloroquine resistance. It is associated 
with mutations in the pfmdr1 (10) and pfcrt (11) genes. 
Nevertheless, the mechanism of quinine resistance is still 
unknown. In addition to the pfmdr1 and pfcrt genes, other 
genetic polymorphisms such as microsatellite length vari-
ations in the P. falciparum sodium/hydrogen exchanger 
(pfnhe-1) gene (5) and mutations in the P. falciparum 
multidrug resistance protein gene may contribute to qui-
nine resistance (12).
We report an association of clinical failure of quinine 
treatment with an IC50 of 829 nmol/L, a mutation in codon 
76 of the pfcrt gene, and an ms4760–18 proﬁ  le for pfnhe-1 
composed of 2 DNNND repeats. Isolates of P. falciparum 
with >2 DNNND repeats may be associated with reduced 
susceptibility to quinine. Henry et al. (5) reported that 2 
DNNND repeats were associated with quinine IC50 values 
ranging from 300 nmol/L to 700 nmol/L, and that 3 repeats 
were associated with an IC50 >600 nmol/L. However, the 
3 strains with IC50s >800 nmol/L had >2 DNNND repeats 
(6). Our results are consistent with these data.
P. falciparum resistance levels may differ depending 
on malaria transmission and drug pressure. Data from Sen-
egal are fragmentary and were obtained by in vitro suscep-
tibility studies conducted with isolates reported to have de-
creased in vitro susceptibility to quinine (6). Our patient had 
traveled to Dielmo, Senegal, where in vitro surveillance of 
antimalarial drug susceptibility has been conducted since 
1996. During 1996–2005, the overall prevalence of isolates 
with IC50 >800 nmol/L for quinine was <6%: 1% in 1996, 
4% in 1997, 0% in 1998, 6% in 1999, and 0% in 2005 (13). 
Quinine was used for 96.4% of the treatments administered 
in Dielmo during 1990–1995 (14). This drug has since been 
replaced by chloroquine, sulfadoxine-pyrimethamine, and 
artemisinin-based combination therapies. 
We report a patient with clinical failure associated qui-
nine resistance in a traveler to Senegal. Our results are con-
sistent with those of a recent review of the Uganda Malaria 
Surveillance Project that reported a higher risk for selecting 
quinine-resistant parasites associated with a 7-day quinine 
treatment course (15). Thus, resistance to quinine should be 
monitored in West Africa. Although such clinical failure of 
therapy is rare, increased vigilance is required during treat-
ment follow-up, and surveillance of the parasite population 
should also be increased.
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Table. In vitro susceptibility of 3 Plasmodium falciparum isolates to 12 antimalarial drugs, France* 
50% Inhibitory concentration 
Drug  Study isolate  3D7  W2  Cutoff value 
Quinine  829 nmol/L  157 nmol/L  574 nmol/L  >800 nmol/L 
Chloroquine  472 nmol/L  21 nmol/L  392 nmol/L  >100 nmol/L 
Mefloquine  10.4 nmol/L  49.3 nmol/L  39.3 nmol/L  >30 nmol/L 
Lumefantrine  19 nmol/L  29 nmol/L  35 nmol/L  >150 nmol/L 
Monodesethylamodiaquine  47 nmol/L  17 nmol/L  162 nmol/L  >80 nmol/L 
Dihydroartemisinin  1.1 nmol/L  2.5 nmol/L  3.0 nmol/L  >10.5 nmol/L 
Atovaquone  13.3 nmol/L  4.1 nmol/L  3.6 nmol/L  >350 nmol/L 
Cycloguanil  70 nmol/L  <10 nmol/L  1191 nmol/L  >500 nmol/L 
Pyrimethamine  354 nmol/L  <50 nmol/L  9139 nmol/L  >2,000 nmol/L 
Doxycycline 12.8  ȝmol/L 10.5  ȝmol/L 13.5  ȝmol/L >35  ȝmol/L 
Azithromycin 24  ȝmol/L 48  ȝmol/L 39  ȝmol/L ND 
Clindamycin 39  ȝmol/L 108  ȝmol/L 126  ȝmol/L ND 
*P. falciparum strains 3D7 and W2 were used as controls. ND, not determined. References
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